bshah

[Raul Cordoba, MD, PhD @DrRaulCordoba]

#Hematology Lenalidomide plus rituximab for previously untreated advanced follicular #lymphoma: the 10-year RELEVANCE trial analysis #lymsm https://t.co/9t98v0ahD3

[Raul Cordoba, MD, PhD @DrRaulCordoba]

#EHA2026 Use of bispecific antibodies as bridging therapy before #CARTcell #lymsm

[Moffitt Cancer Center @MoffittNews]

Catch Moffitt’s Todd Knepper, PharmD, tomorrow at #EHA2026, where he will share new research during the Stem Cell Transplantation - Clinical 1 session, examining how post-transplant molecular surveillance can reveal distinct clinical trajectories associated with donor-derived clonal hematopoiesis. #MoffittEHA2026 @EHA_Hematology

[ALL Hub @ALL_Hub_]

CONGRESS | #ASCO26 | PRESENTATION
Shannon Maude shares findings from the primary analysis of a phase II trial (COG AALL1721/CASSIOPEIA), in collaboration with COG, of tisagenlecleucel (tisa-cel) in pediatric and young adult patients (1-25 years of age) with high-risk (HR) B-cell ALL and MRD at the end of frontline consolidation (N = 121).

Median time from infusion to last follow-up was 38 months. The primary end point was met; 4-year OS was 85%. Estimated 5-year DFS with and without censoring was 62% and 64%, respectively. 48% of patients received new anticancer therapy/SCT without prior relapse. Median duration of B-cell aplasia was 5.6 months. Grade ≥3 CRS and ICANS occurred in 2% and 1% of patients, respectively.
Durable remissions and low rates of Grade ≥3 CRS and ICANS were observed with tisa-cel in very HR patients with B-cell ALL. Longer follow-up is needed to confirm the 5-year DFS.

Follow our live feed for more updates: https://t.co/RFQ91v2Mcm

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.

#ALLsm #leusm #MedNews #MedEd #MedicalCongress @ChildrensPhila

[Moffitt Cancer Center @MoffittNews]

During the last morning poster session at #ASCO26, Kriti Gera, MD (@kriti_gera_), shares research comparing lymphodepletion strategies before CD19 CAR-T therapy, highlighting findings that suggest a potentially safer approach without compromising efficacy for patients with B-cell acute lymphoblastic leukemia. #MoffittASCO26

[Lymphoma Hub @lymphomahub]

New publication 📝 5-year follow-up results from the ZUMA-2 trial, published in the Journal of Hematology & Oncology, show brexu-cel produced durable responses in R/R MCL, with a median DoR of 36.5 months.
Learn more: https://t.co/DNvS3ZXgX6

#lymsm #MedNews #MedEd

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC article: "Clinical outcomes and spatial transcriptomic profiles of CD19/20 CAR-T therapy in relapsed or refractory B-cell non-Hodgkin’s lymphoma" https://t.co/yUTvCaz3OI

[VJHemOnc @VJHemOnc]

We recently spoke with @LancetJeff of @MoffittNews to gain insight into the updated ASH guidelines for the management of older patients with newly diagnosed AML.🩸

In this video, Dr Lancet discusses how to decide which patients should be offered antileukemic therapy:

🎥 https://t.co/UDaG7RuMtX

#Leusm #Leukemia #AMLsm #HemOnc

[Yumeng (Julia) Zhang @yumengzhang2009]

So honored to be featured by PETAL. A lot of work to do for PTCL!

[bshah @bshah]

@jaybradner @ericchurch Beautifully resonant - except for the Duke part :) thanks for sharing

[Toby Eyre @tobyeyre82]

BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma - https://t.co/5cjKG42QLq

[Marcos de Lima @DrMarcosdelima]

Any surprise here ?

[Raul Cordoba, MD, PhD @DrRaulCordoba]

#Hematology Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in TP53-Mutated Diffuse Large B-Cell #Lymphoma | Journal of Clinical Oncology ⁦@JCO_ASCO⁩ #lymsm https://t.co/66aZWjJGOD

[Moffitt Cancer Center @MoffittNews]

At the International Workshop on CAR-T and Bispecifics (#iwCART26), Moffitt’s Bijal Shah, MD, presented on where CAR T-cell therapy in B-ALL is headed next.

His talk highlighted how today’s CAR T therapies are already outperforming commercial alternatives while the field continues to move toward “CAR 2.0.”

Dr. Shah explored the next generation of CAR strategies, including improved access, dual-antigen targeting, T-cell engineering, cytokine armoring, metabolic resilience and targeted insertion — all aimed at making CAR T-cell therapy more durable, accessible and effective for patients.

[Al-Ola A Abdallah MD (USMIRC) @Abdallah81MD]

🚨🔥 BIG NEWS | #ICETCongress 2026 🔥🚨

Get ready, Orlando! 🌴

📍 Orlando, FL
🗓 July 18, 2026

The National ICE-T Congress is back—bigger, bolder, and pushing the future of #CellTherapy forward 🚀

⭐ Led by powerhouse chairs: @heMEGirl_MD @HemSandoval and ICE-T Executive Director:@kczmj

⚡ CAR-T
⚡ Bispecifics
⚡ Real-world innovation
⚡ Multidisciplinary impact

This is where the future of hematology meets action. Don’t miss it.
@NausheenAhmedMD Jennifer DeVore

[Yi Lin @YiLinMDPhD]

#iwCART26 kicks off today with #CellTherapies in solid tumors & autoimmune diseases. @VJHemOnc @DrKedarKirtane @DrFredLocke https://t.co/OZjmOhXW0I

[Sanam Loghavi, MD صنم لغوی 🔬🧬 @sanamloghavi]

🚨 PSA: there is an organized hacking effort going on targeting medical accounts on X/Twitter . 3 of my friends were hacked. If U get a DM from someone U know asking U to click on a link & vote for them for an ambassador program, DO NOT click. Report the account.

[Toby Eyre @tobyeyre82]

Mosunetuzumab plus polatuzumab vedotin in relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study https://t.co/4z1tk3fD5i

[Eddie Cliff @Eddie_Cliff]

In this week's issue of @BloodPortfolio, our study of global access to CAR T, led by Alex Ge.

Thanks to Blood editors for making it a plenary paper!

Free access link: https://t.co/0H4HwFGL3V

Thanks @kjmeetswrld for the thoughtful commentary
https://t.co/5jPIl0h2Mm

[bshah @bshah]

@HemSandoval I think we could say that about nearly every pharma sponsored trial that is published - so some nuance to this. Again, I don’t think we should abandon scrutiny (be it clinical retro data or a phase 3) - but I don’t agree that it means inherent bias